Clinical trial
Value of Liver Stiffness Measurement (LSM) in Predicting the Progress of Liver Fibrosis After Transcatheter Arterial Chemoembolization (TACE) for Hepatocellular Carcinoma, an Observational Study
NCT03285867 is registered in ClinicalTrials.gov with Nanfang Hospital, Southern Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Value of Liver Stiffness Measurement (LSM) in Predicting the Progress of Liver Fibrosis After Transcatheter Arterial Chemoembolization (TACE) for Hepatocellular Carcinoma, an Observational Study
- Lead sponsor
- Nanfang Hospital, Southern Medical University
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- June 25, 2018
- Completion date
- December 31, 2021
- Enrollment
- 200 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
hepatocellular carcinoma, liver failure